JP2005505293A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505293A5
JP2005505293A5 JP2003535704A JP2003535704A JP2005505293A5 JP 2005505293 A5 JP2005505293 A5 JP 2005505293A5 JP 2003535704 A JP2003535704 A JP 2003535704A JP 2003535704 A JP2003535704 A JP 2003535704A JP 2005505293 A5 JP2005505293 A5 JP 2005505293A5
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
acid molecule
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003535704A
Other languages
English (en)
Japanese (ja)
Other versions
JP5329016B2 (ja
JP2005505293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/023475 external-priority patent/WO2003032898A2/en
Publication of JP2005505293A publication Critical patent/JP2005505293A/ja
Publication of JP2005505293A5 publication Critical patent/JP2005505293A5/ja
Application granted granted Critical
Publication of JP5329016B2 publication Critical patent/JP5329016B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003535704A 2001-07-23 2002-07-23 修飾したヒト胸腺ストローマ細胞リンホポエチン Expired - Lifetime JP5329016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30734501P 2001-07-23 2001-07-23
US60/307,345 2001-07-23
PCT/US2002/023475 WO2003032898A2 (en) 2001-07-23 2002-07-23 Modified human thymic stromal lymphopoietin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010153133A Division JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Publications (3)

Publication Number Publication Date
JP2005505293A JP2005505293A (ja) 2005-02-24
JP2005505293A5 true JP2005505293A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP5329016B2 JP5329016B2 (ja) 2013-10-30

Family

ID=23189325

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003535704A Expired - Lifetime JP5329016B2 (ja) 2001-07-23 2002-07-23 修飾したヒト胸腺ストローマ細胞リンホポエチン
JP2010153133A Pending JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010153133A Pending JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Country Status (11)

Country Link
US (9) US7288633B2 (cg-RX-API-DMAC7.html)
EP (1) EP1417231B1 (cg-RX-API-DMAC7.html)
JP (2) JP5329016B2 (cg-RX-API-DMAC7.html)
AU (1) AU2002359238B2 (cg-RX-API-DMAC7.html)
CA (1) CA2454578C (cg-RX-API-DMAC7.html)
DK (1) DK1417231T3 (cg-RX-API-DMAC7.html)
ES (1) ES2422879T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000631A (cg-RX-API-DMAC7.html)
PL (1) PL371773A1 (cg-RX-API-DMAC7.html)
PT (1) PT1417231E (cg-RX-API-DMAC7.html)
WO (1) WO2003032898A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ES2384960T3 (es) * 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
EP1651247B1 (en) * 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
DK2197903T3 (en) * 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
US11001624B2 (en) 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
CA2118119C (en) 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
GB9209874D0 (en) 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
CA2349762C (en) 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
GB2381685A (en) 2001-10-30 2003-05-07 Amino Holdings Ltd Gateway device for converting digital signals to analogue signals
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
EP1651247B1 (en) 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물

Similar Documents

Publication Publication Date Title
US12516116B2 (en) Homodimeric protein constructs
ES2329334T3 (es) Formas multimericas de ligandos de la superfamilia de tnf.
EP3319633B1 (en) Vaccine against rsv
ES3064850T3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2012520059A5 (cg-RX-API-DMAC7.html)
AU2012311238A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
AU2018351209B2 (en) Mutant of H3N2 subtype influenza virus hemagglutinin protein and use thereof
JP2025521082A5 (cg-RX-API-DMAC7.html)
JP2023542453A5 (cg-RX-API-DMAC7.html)
CN1989150A (zh) 免疫原性复合物、其制备方法及其在药物组合物中的应用
WO2022098913A2 (en) Compositions for inducing protective immune response against sars-cov-2 infection
ES2706058T3 (es) Constructos de proteínas homodiméricas
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
WO2023020637A1 (es) Antigenos quimericos para el control de coronavirus y composiciones que los comprenden
WO2025222028A1 (en) Design of universal h5 influenza virus vaccine candidates via antigen reorientation
BR112012032922B1 (pt) Proteína homodimérica, molécula de ácido nucleico, composição farmacêutica, método para a preparação de uma proteína homodimérica, e, vacina
HK1250939B (en) Vaccine against rsv